Axicabtagene Ciloleucel Expanded Access Study — ZUMA-9  

Relapsed/Refractory Diffuse Large B Cell Lymphoma Clinical Trial

Official title: A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-cell Lymphoma.

Status Approved for marketing

Clinical Trial Summary

A multicenter, open-label expanded access protocol for the treatment of subjects with relapsed/refractory large B-cell lymphoma.

Subjects who received an infusion of axicabtagene ciloleucel will complete the remainder of the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Large B-Cell, Diffuse
• Relapsed/Refractory Diffuse Large B Cell Lymphoma
• Relapsed/Refractory High-Grade B-Cell Lymphoma
• Relapsed/Refractory Primary Mediastinal B Cell Lymphoma
• Relapsed/Refractory Transformed Follicular Lymphoma

• NCT number: NCT03153462
• Study type: Expanded Access
• Source: Gilead Sciences
• Status: Approved for marketing